Arvinas logo

Patients

Middle aged woman in gray sweater holding her glasses looking to her right

Expanded Access Policy

Arvinas is a biotechnology company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases.

Expanded access, also called compassionate use, refers to a pathway in which patients with serious or immediately life-threatening diseases may gain access to an investigational therapy outside the context of participation in clinical trials designed to evaluate safety and efficacy.

At this time, we do not have an expanded access program that allows patients to have access to our investigational products prior to FDA approval.

Middle aged woman in gray sweater holding her glasses looking to her right
Middle aged man with glasses looking to his right with arms folded over chest
Middle aged man in green shirt looking to his right

Contact Information

  • If you have any questions about our expanded access policy, please contact Arvinas through the following email address: medicalaffairs@arvinas.com.

  • Information on all ongoing investigational trials sponsored by Arvinas can be found at clinicaltrials.gov
 

As authorized by the 21st Century Cures Act, Arvinas may revise this expanded access policy at any time. Additionally, the posting of this policy by Arvinas shall not serve as a guarantee of access to any specific investigational drug by any individual patient.

Skip to content